Mengmeng Tang
Seminars
Wednesday 18th November 2026
Advancing TIL Therapy in Advanced Melanoma With Clinical Evidence Supporting a Next Generation Treatment Approach
9:30 am
- Presenting pivotal clinical data from patients with advanced melanoma, demonstrating achievement of the study’s primary endpoint and supporting the potential for the first marketed TIL therapy in China
- Exploring innovations in treatment delivery through an IL-2-free regimen, low-intensity pretreatment, and a feeder-free manufacturing process designed to simplify therapy while maintaining clinical efficacy
- Examining outcomes in predominantly acral and mucosal melanoma populations and discussing what these findings could mean for the future evolution of TIL therapy
